La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Tianjin Chase Sun PharmaceuticalLtd Résultats passés
Passé contrôle des critères 1/6
Tianjin Chase Sun PharmaceuticalLtd has been growing earnings at an average annual rate of 12.1%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 6.7% per year. Tianjin Chase Sun PharmaceuticalLtd's return on equity is 4.2%, and it has net margins of 6.6%.
Informations clés
12.1%
Taux de croissance des bénéfices
11.9%
Taux de croissance du BPA
| Pharmaceuticals Croissance de l'industrie | 10.9% |
| Taux de croissance des recettes | 6.7% |
| Rendement des fonds propres | 4.2% |
| Marge nette | 6.6% |
| Prochaine mise à jour des résultats | 30 Aug 2024 |
Mises à jour récentes des performances passées
Recent updates
These 4 Measures Indicate That Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Is Using Debt Reasonably Well
Aug 02
There's No Escaping Tianjin Chase Sun Pharmaceutical Co.,Ltd's (SZSE:300026) Muted Earnings
Jun 12Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Has Announced A Dividend Of CN¥0.03
May 22This Broker Just Slashed Their Tianjin Chase Sun Pharmaceutical Co.,Ltd (SZSE:300026) Earnings Forecasts
May 21Tianjin Chase Sun PharmaceuticalLtd's (SZSE:300026) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Apr 04Ventilation des recettes et des dépenses
Comment Tianjin Chase Sun PharmaceuticalLtd gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Mar 24 | 5,913 | 389 | 2,450 | 204 |
| 31 Dec 23 | 6,109 | 507 | 2,515 | 210 |
| 30 Sep 23 | 6,672 | 663 | 2,826 | 209 |
| 30 Jun 23 | 6,762 | 617 | 2,971 | 220 |
| 31 Mar 23 | 6,577 | 561 | 2,859 | 229 |
| 01 Jan 23 | 6,650 | 624 | 2,807 | 231 |
| 30 Sep 22 | 7,084 | 521 | 3,026 | 257 |
| 30 Jun 22 | 7,496 | 602 | 3,099 | 231 |
| 31 Mar 22 | 7,764 | 732 | 3,133 | 207 |
| 31 Dec 21 | 7,671 | 687 | 3,128 | 197 |
| 30 Sep 21 | 7,266 | 611 | 2,837 | 197 |
| 30 Jun 21 | 7,192 | 667 | 2,846 | 198 |
| 31 Mar 21 | 7,001 | 657 | 2,811 | 195 |
| 31 Dec 20 | 6,488 | 573 | 2,717 | 177 |
| 30 Sep 20 | 6,109 | 485 | 2,708 | 161 |
| 30 Jun 20 | 5,497 | 396 | 2,565 | 161 |
| 31 Mar 20 | 5,085 | 337 | 2,553 | 174 |
| 31 Dec 19 | 5,003 | 403 | 2,534 | 179 |
| 30 Sep 19 | 4,796 | 264 | 2,513 | 166 |
| 30 Jun 19 | 4,548 | 216 | 2,412 | 161 |
| 31 Mar 19 | 4,303 | 219 | 2,267 | 143 |
| 31 Dec 18 | 4,224 | 211 | 2,210 | 141 |
| 30 Sep 18 | 4,015 | 463 | 2,016 | 126 |
| 30 Jun 18 | 3,894 | 514 | 1,876 | 161 |
| 31 Mar 18 | 3,605 | 485 | 1,713 | 134 |
| 31 Dec 17 | 3,374 | 451 | 1,618 | 109 |
| 30 Sep 17 | 3,543 | 633 | 1,694 | 70 |
| 30 Jun 17 | 3,564 | 630 | 1,818 | 0 |
| 31 Mar 17 | 3,743 | 666 | 1,982 | 0 |
| 31 Dec 16 | 3,867 | 659 | 2,100 | 0 |
| 30 Sep 16 | 3,722 | 582 | 2,211 | 0 |
| 30 Jun 16 | 3,635 | 599 | 2,195 | 0 |
| 31 Mar 16 | 3,596 | 572 | 2,237 | 0 |
| 31 Dec 15 | 3,348 | 535 | 2,153 | 0 |
| 30 Sep 15 | 3,187 | 541 | 1,988 | 0 |
| 30 Jun 15 | 3,076 | 474 | 1,961 | 0 |
| 31 Mar 15 | 2,969 | 452 | 1,922 | 0 |
| 31 Dec 14 | 2,864 | 447 | 1,860 | 0 |
| 30 Sep 14 | 2,681 | 421 | 1,756 | 0 |
| 30 Jun 14 | 2,405 | 395 | 1,562 | 0 |
| 31 Mar 14 | 2,201 | 362 | 1,418 | 0 |
| 31 Dec 13 | 2,097 | 340 | 1,349 | 0 |
| 30 Sep 13 | 1,862 | 308 | 1,174 | 0 |
Des revenus de qualité: 300026 has a large one-off gain of CN¥151.1M impacting its last 12 months of financial results to 31st March, 2024.
Augmentation de la marge bénéficiaire: 300026's current net profit margins (6.6%) are lower than last year (8.5%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: 300026's earnings have grown by 12.1% per year over the past 5 years.
Accélération de la croissance: 300026's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Bénéfices par rapport au secteur d'activité: 300026 had negative earnings growth (-30.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.8%).
Rendement des fonds propres
ROE élevé: 300026's Return on Equity (4.2%) is considered low.